Drug class
Pseudomembranous Colitis Agents
"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class. Read more about Pseudomembranous Colitis Agents
55 drugs in this class 45 manufacturers
Drugs in Pseudomembranous Colitis Agents
DIFICID (fidaxomicin)
DIFICID (fidaxomicin)
VANCOCIN (vancomycin HCl)
LIKMEZ (metronidazole)
METRONIDAZOLE
METRONIDAZOLE
VANCOMYCIN HCL
METRONIDAZOLE
"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class.
It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine.
These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well as metronidazole—work by inhibiting bacterial cell-wall synthesis, RNA polymerase transcription, or DNA replication locally within the gastrointestinal tract.
Consequently, their primary therapeutic application is the treatment and clinical resolution of acute or recurrent *C.
difficile*–associated diarrhea and pseudomembranous colitis.
-
drugs.com
"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well ...
-
mayoclinic.org
It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine
-
nih.gov
It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine
-
nih.gov
These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well as metronidazole—work by inhibiting bacterial cell-wall synthesis, RNA polymerase transcription, or DNA replication locally within the gastrointestinal tract Consequently, their primary therapeutic application is the treatment and clinical resolution of acute or recurrent *C. difficile*–associated diarrhea and pseudomembranous colitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.